Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Next Previous
X
Search
Trial Profile

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary) ; Cisplatin
  • Indications Chemotherapy-induced damage; Hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NOTOXIS
  • Sponsors Sensorion

    • Most Recent Events

    • 02 Sep 2024 According to a Sensorion media release, the company announced its participation in the 36th World Congress of Audiology (WCA), this session will focus on the therapeutic advances in hearing preservation associated with Cisplatin-Induced Ototoxicity
    • 23 Jul 2024 According to a Sensorion media release, patient enrolment continues to progress at a steady pace, in 13 clinical centers open to date.
    • 23 Jul 2024 According to a Sensorion media release, company today announces independent Data Safety Monitoring Board (or DSMB) has undertaken a review of safety data for patients participating in NOTOXIS Phase 2a Proof-of-Concept (POC) clinical study of SENS-401 for the prevention of Cisplatin-Induced Ototoxicity (CIO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top